BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE:SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the...
CHICAGO, Oct. 30 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for CSCO, SGP, BHP, COST, and AEO. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
KENILWORTH, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP) today announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be...
BOXMEER, Netherlands, Oct. 8 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health today announced that it has initiated a multi-year sponsorship project, supporting the Shire...
CHICAGO, Oct. 7 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MSFT, SGP, AUY, WFMI, and ACH. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one...
KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to...
KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate...
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관